What's new

Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive

Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive

Apr 4, 2025 - 12:53
 0
Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive
Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive
Read More

Tags:

Previous Article

Mandarin Oriental Expands its Parisian Presence with the Iconic Hôtel Lutetia on...

Next Article

Lindner Hotels: ongoing restructuring process on track

Related Posts

Substances considered as not falling within the scope o...

Feb 21, 2025  0

Human medicines European public assessment report (EPAR): Entyvio, vedolizumab, Date of authorisation: 22/05/2014, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 13, 2025  0

Orphan designation: Venetoclax Treatment of mantle cell lymphoma, 12/12/2017 Withdrawn

Orphan designation: Venetoclax Treatment of mantle cell...

Mar 11, 2025  0